Finasteride 1 mg tablets are approved for treating male pattern hair loss, while the 5 mg strength is indicated for benign prostatic hyperplasia (BPH). The higher dose targets prostate enlargement and is not required for hair-loss therapy.
Finpecia can be used concurrently with topical minoxidil, as they act through different mechanisms. However, both treatments should be discussed with a healthcare professional to ensure suitability and monitor any combined side effects.
Visible improvement typically begins after 3 to 6 months of consistent daily use. Full benefits may take up to a year, and continued treatment is necessary to maintain results.
Finasteride can lower PSA levels by about 50 % after several months of therapy. Clinicians should adjust PSA interpretation accordingly, often by doubling the measured value to approximate the true baseline.
Older men should have liver function evaluated before starting therapy and undergo regular PSA monitoring, as the risk of prostate changes may be higher in this age group.
Rare case reports have linked finasteride to depressive symptoms and mood alterations. If persistent mood changes occur, patients should seek medical advice promptly.
Yes, provided the medication is kept in its original packaging with a copy of the prescription. Some countries may require a doctor’s note for prescription medications, so carry documentation when crossing borders.
Do not double the next dose. If an overdose is suspected and symptoms such as dizziness or faintness appear, seek medical attention. In most cases, an extra tablet does not cause serious harm.
Alcohol does not directly interact with finasteride, but excessive drinking can exacerbate sexual side effects, such as reduced libido or erectile difficulty.
Unused tablets should be returned to a pharmacy’s medication-take-back scheme or disposed of according to NHS guidelines-mixing them with an unpalatable substance, placing them in a sealed container, and discarding in household waste.
Finpecia is a brand-name medication that contains the active ingredient finasteride. It is marketed as a 1 mg oral pill and is classified within the men’s health therapeutic area. In the United Kingdom, Finpecia is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Finasteride belongs to the class of 5α-reductase inhibitors, which are used to treat conditions related to the hormone dihydrotestosterone (DHT).
Finasteride blocks the enzyme 5α-reductase type II. This enzyme normally converts testosterone into the more potent androgen dihydrotestosterone (DHT). By inhibiting this conversion:
Finpecia is approved by the MHRA for male pattern hair loss (androgenetic alopecia) in adult men. The medication is indicated for use when hair thinning is evident on the crown and vertex of the scalp. It is not approved for treating benign prostatic hyperplasia (BPH) at the 1 mg strength; the 5 mg formulation is used for that indication.
Finasteride has been studied off-label for:
Disclaimer: Off-label use requires medical supervision and an individualized risk-benefit assessment.
Finasteride has a low potential for drug-drug interactions, but clinicians should be aware of:
This article provides educational information about Finpecia and is not a substitute for professional medical advice. Treatment decisions, including the use of Finpecia for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
